Neuraminidase inhibitor therapy in a military population

Mary P. Fairchok, Wei Ju Chen, John C. Arnold, Christina Schofield, Patrick J. Danaher, Erin A. McDonough, Martin Ottolini, Deepika Mor, Michelande Ridore, Timothy H. Burgess, Eugene V. Millar

Research output: Contribution to journalArticle

Abstract

Background: Although neuraminidase inhibitors (NI) are the mainstay of treatment for influenza infection, prescribing practice for these agents is not well described. Additionally, benefit is contested. Objectives: We examined provider prescriptions of NI during the 2009 pandemic and post-pandemic periods. We also evaluated the effectiveness of NI in reducing severity of influenza infection. Study design: Data on NI prescription and severity of influenza infection were compiled in healthy pediatric and adult beneficiaries enrolled in a prospective study of influenza like illness conducted at five military medical centers over five years. Subjects underwent nasal swabs to determine viral etiology of their infection. Demographic, medication and severity data were collected. Subjects with positive influenza were included. Results: Two hundred sixty three subjects were influenza positive [38% [H1N1] pdm09, 38.4% H3N2, and 20.5% B); 23.9% were treated with NI. NI were initiated within 48. h in 63% of treated subjects. Although NI use increased over the five years of the study, early use declined. Most measures for severity of illness were not significantly reduced with NI; adults treated within 48. h had only a modest reduction in duration and severity of some of their symptoms. Conclusions: NI use in our population is increasing, but early use is not. NI use resulted in no reduction in complications of illness. Resolution of symptoms and reduction in severity of some symptoms were slightly better in adults who were treated early. These modest benefits do not support routine treatment with NI in otherwise healthy individuals with influenza.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalJournal of Clinical Virology
Volume67
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Neuraminidase
Human Influenza
Population
Therapeutics
Pandemics
Infection
Prescriptions
Nose
Demography
Prospective Studies
Pediatrics

Keywords

  • Antivirals
  • Influenza
  • Neuraminidase inhibitors
  • Prescription
  • Severity

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Fairchok, M. P., Chen, W. J., Arnold, J. C., Schofield, C., Danaher, P. J., McDonough, E. A., ... Millar, E. V. (2015). Neuraminidase inhibitor therapy in a military population. Journal of Clinical Virology, 67, 17-22. https://doi.org/10.1016/j.jcv.2015.03.018

Neuraminidase inhibitor therapy in a military population. / Fairchok, Mary P.; Chen, Wei Ju; Arnold, John C.; Schofield, Christina; Danaher, Patrick J.; McDonough, Erin A.; Ottolini, Martin; Mor, Deepika; Ridore, Michelande; Burgess, Timothy H.; Millar, Eugene V.

In: Journal of Clinical Virology, Vol. 67, 01.06.2015, p. 17-22.

Research output: Contribution to journalArticle

Fairchok, MP, Chen, WJ, Arnold, JC, Schofield, C, Danaher, PJ, McDonough, EA, Ottolini, M, Mor, D, Ridore, M, Burgess, TH & Millar, EV 2015, 'Neuraminidase inhibitor therapy in a military population', Journal of Clinical Virology, vol. 67, pp. 17-22. https://doi.org/10.1016/j.jcv.2015.03.018
Fairchok MP, Chen WJ, Arnold JC, Schofield C, Danaher PJ, McDonough EA et al. Neuraminidase inhibitor therapy in a military population. Journal of Clinical Virology. 2015 Jun 1;67:17-22. https://doi.org/10.1016/j.jcv.2015.03.018
Fairchok, Mary P. ; Chen, Wei Ju ; Arnold, John C. ; Schofield, Christina ; Danaher, Patrick J. ; McDonough, Erin A. ; Ottolini, Martin ; Mor, Deepika ; Ridore, Michelande ; Burgess, Timothy H. ; Millar, Eugene V. / Neuraminidase inhibitor therapy in a military population. In: Journal of Clinical Virology. 2015 ; Vol. 67. pp. 17-22.
@article{42b4fd859bd0439799d7ed65fcfc41a4,
title = "Neuraminidase inhibitor therapy in a military population",
abstract = "Background: Although neuraminidase inhibitors (NI) are the mainstay of treatment for influenza infection, prescribing practice for these agents is not well described. Additionally, benefit is contested. Objectives: We examined provider prescriptions of NI during the 2009 pandemic and post-pandemic periods. We also evaluated the effectiveness of NI in reducing severity of influenza infection. Study design: Data on NI prescription and severity of influenza infection were compiled in healthy pediatric and adult beneficiaries enrolled in a prospective study of influenza like illness conducted at five military medical centers over five years. Subjects underwent nasal swabs to determine viral etiology of their infection. Demographic, medication and severity data were collected. Subjects with positive influenza were included. Results: Two hundred sixty three subjects were influenza positive [38{\%} [H1N1] pdm09, 38.4{\%} H3N2, and 20.5{\%} B); 23.9{\%} were treated with NI. NI were initiated within 48. h in 63{\%} of treated subjects. Although NI use increased over the five years of the study, early use declined. Most measures for severity of illness were not significantly reduced with NI; adults treated within 48. h had only a modest reduction in duration and severity of some of their symptoms. Conclusions: NI use in our population is increasing, but early use is not. NI use resulted in no reduction in complications of illness. Resolution of symptoms and reduction in severity of some symptoms were slightly better in adults who were treated early. These modest benefits do not support routine treatment with NI in otherwise healthy individuals with influenza.",
keywords = "Antivirals, Influenza, Neuraminidase inhibitors, Prescription, Severity",
author = "Fairchok, {Mary P.} and Chen, {Wei Ju} and Arnold, {John C.} and Christina Schofield and Danaher, {Patrick J.} and McDonough, {Erin A.} and Martin Ottolini and Deepika Mor and Michelande Ridore and Burgess, {Timothy H.} and Millar, {Eugene V.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jcv.2015.03.018",
language = "English (US)",
volume = "67",
pages = "17--22",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",

}

TY - JOUR

T1 - Neuraminidase inhibitor therapy in a military population

AU - Fairchok, Mary P.

AU - Chen, Wei Ju

AU - Arnold, John C.

AU - Schofield, Christina

AU - Danaher, Patrick J.

AU - McDonough, Erin A.

AU - Ottolini, Martin

AU - Mor, Deepika

AU - Ridore, Michelande

AU - Burgess, Timothy H.

AU - Millar, Eugene V.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background: Although neuraminidase inhibitors (NI) are the mainstay of treatment for influenza infection, prescribing practice for these agents is not well described. Additionally, benefit is contested. Objectives: We examined provider prescriptions of NI during the 2009 pandemic and post-pandemic periods. We also evaluated the effectiveness of NI in reducing severity of influenza infection. Study design: Data on NI prescription and severity of influenza infection were compiled in healthy pediatric and adult beneficiaries enrolled in a prospective study of influenza like illness conducted at five military medical centers over five years. Subjects underwent nasal swabs to determine viral etiology of their infection. Demographic, medication and severity data were collected. Subjects with positive influenza were included. Results: Two hundred sixty three subjects were influenza positive [38% [H1N1] pdm09, 38.4% H3N2, and 20.5% B); 23.9% were treated with NI. NI were initiated within 48. h in 63% of treated subjects. Although NI use increased over the five years of the study, early use declined. Most measures for severity of illness were not significantly reduced with NI; adults treated within 48. h had only a modest reduction in duration and severity of some of their symptoms. Conclusions: NI use in our population is increasing, but early use is not. NI use resulted in no reduction in complications of illness. Resolution of symptoms and reduction in severity of some symptoms were slightly better in adults who were treated early. These modest benefits do not support routine treatment with NI in otherwise healthy individuals with influenza.

AB - Background: Although neuraminidase inhibitors (NI) are the mainstay of treatment for influenza infection, prescribing practice for these agents is not well described. Additionally, benefit is contested. Objectives: We examined provider prescriptions of NI during the 2009 pandemic and post-pandemic periods. We also evaluated the effectiveness of NI in reducing severity of influenza infection. Study design: Data on NI prescription and severity of influenza infection were compiled in healthy pediatric and adult beneficiaries enrolled in a prospective study of influenza like illness conducted at five military medical centers over five years. Subjects underwent nasal swabs to determine viral etiology of their infection. Demographic, medication and severity data were collected. Subjects with positive influenza were included. Results: Two hundred sixty three subjects were influenza positive [38% [H1N1] pdm09, 38.4% H3N2, and 20.5% B); 23.9% were treated with NI. NI were initiated within 48. h in 63% of treated subjects. Although NI use increased over the five years of the study, early use declined. Most measures for severity of illness were not significantly reduced with NI; adults treated within 48. h had only a modest reduction in duration and severity of some of their symptoms. Conclusions: NI use in our population is increasing, but early use is not. NI use resulted in no reduction in complications of illness. Resolution of symptoms and reduction in severity of some symptoms were slightly better in adults who were treated early. These modest benefits do not support routine treatment with NI in otherwise healthy individuals with influenza.

KW - Antivirals

KW - Influenza

KW - Neuraminidase inhibitors

KW - Prescription

KW - Severity

UR - http://www.scopus.com/inward/record.url?scp=84928893926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928893926&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2015.03.018

DO - 10.1016/j.jcv.2015.03.018

M3 - Article

AN - SCOPUS:84928893926

VL - 67

SP - 17

EP - 22

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -